A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications were considered. The guidelines were then revised after extensive feedback from participants and interested parties. A literature review is provided which identifies the quality of evidence upon which the recommendations are made. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment. Significant changes since the last guidelines were published in 2008 include the availability of new antidepressant treatment options, improved evidence supporting certain augmentation strategies (drug and non-drug), management of potential long-term side effects, updated guidance for prescribing in elderly and adolescent populations and updated guidance for optimal prescribing. Suggestions for future research priorities are also made.
抗抑郁症药物近年来发展迅速,其品种已超过20多种。目前,除三环类(tricyclic antidepressants,TCAs)作为经典抗抑郁症药仍保留TCAs这个名称外,国内外较多按作用机制划分命名,主要包括[9]:①5-HT再摄取抑制药(selective serotonin reuptake inhibitor,SSRIs),如氟西汀、帕罗西汀、舍曲林、氟伏沙明、西酞普兰和艾司西酞普兰;②选择性5-HT及NE再摄取抑制药(selective serotonin-norepinephrine reuptake inhibitors,SNRIs),如文拉法辛、度洛西汀;③NE及特异性5-HT能抗抑郁症药(noradrenergic and specific serotonergic antidepressant,NaSSA) ,如米氮平;④NE及DA再摄取抑制药(norepinephrine-dopamine reuptake inhibitors,NDRIs),如安非他酮;⑤5-HT2A受体拮抗药及5-HT再摄取抑制药(serotonin receptor antagonists reuptake inhibitor,SARIs),如曲唑酮、奈法唑酮;⑥单胺氧化酶抑制药(monoamine oxidase inhibitors,MAOIs),如苯乙肼、环苯丙胺及新一代可逆性MAOIs吗氯贝胺。除TCAs和MAOIs作为经典的第一代抗抑郁症药,上述药物多属于新一代抗抑郁症药。

声明:此回答是一名长期抑郁症患者的经验总结,原文适用于中度抑郁症及以下自救,更新适用于想要关爱身边抑郁症患者的朋友。虽然本人读过不少关于抑郁症的书(此文设计基本概念都有权威出处),参加过一些关于抑郁,焦虑,自信心的正规医疗自救培训,但目前本人没有经过任何正规系统的专业学习,答案中的任何观点都属于完全业余,严肃问题请一定寻医问诊,欢迎指正。话题经验相关:我本人因为博士转专业和实验不顺长期抑郁。我有一个非常善良温柔三观正,并陪伴我多年的男朋友(非抑郁症),感谢他的存在。鉴于有太多很爱护自己另一半的朋友问我这个问题,想要为身边患有抑郁症的朋友做些什么却又不知道该怎么做;我觉得有必要在这里简明扼要地地说明几个问题及注意事项。又以及,鄙原文上传后的这些年获得了一些新的知识和感受,我在这里做一次更新。-20160527


根据目前国内外抑郁症药物治疗指南,一般推荐SSRIs、SNRIs、NaSSAs等新一代抗抑郁症药作为首选药物。在我国部分地区,由于经济限制,TCAs如阿米替林、氯米帕明、麦普替林等仍作为一线治疗药物[9]。抗抑郁症药物具有不同的作用机制及不良反应,对每个人的治疗应答也不尽相同,合理选择与应用药物尤为重要。英国精神药理协会(British Association for Psychopharmacology,BAP)对目前一线抗抑郁症药物治疗疗效进行进一步文献荟萃分析,在其更新的循证医学指南 [11] 中指出,相比于SSRIs,双通道阻断药SNRIs(如文拉法辛)可能具有更高的特异性及更好的疗效;而在SSRIs中,艾司西酞普兰的疗效可能优于其他SSRIs;综合考虑治疗应答率、疗效、耐受性等因素时,选择舍曲林及艾司西酞普兰可能治疗效果最佳。
最近忙着写论文,这个贴就被我这么晾着了。还有两个月我就完成大作啦,继续努力~@@!最为偷懒, 最近忙着写论文,这个贴就被我这么晾着了。还有两个月我就完成大作啦,继续努力~@@!最为偷懒,就转自己以前写过的吧。 我发现我的一篇日记总是有人收藏,尤其是最近,平均每几天就有一个人收藏,后台总是给我发来通知。 那就说明这篇帖子的内容是被人需要的,有人在搜索着。 沉默,是会呼吸的痛。我能想象到,在屏幕的那一边,有一个人正在经历着精神上的痛苦,他/她想尽力地帮助自己,不放弃一丝希望。他/她虽什么也没说,但每一天的生活都是真实地痛苦着。 我希望这个帖子能帮助有需要的人好起来。 我相信你能最终好起来。因为至少还有我这样的人,还有很多专业的人士,愿意帮助你。去认识他们,去寻求帮助,你并不孤独。 《长期抑郁该如何治疗?如何预防抑郁症复发?》 https://www.douban.com/note/576926663/ ... aizzibleoK
确诊之后,我开始每天服药治疗,刚开始药物就产生了功效,胸闷和不安的情绪有了些许好转。但是每天依然乏力,无法集中注意力,总是打瞌睡。(后来,医生跟我说,我吃的药里面有安眠药,而且其它几种药物也有犯困的副作用。)服药大概两~三周之后,头晕,紧张的症状开始减少了。大概三个月左右,我感觉自己时不时会有非常清醒的时候,起床后整个大脑非常清醒,就像缺氧的脑袋突然戴上了氧气罐。但是,我吃的药会让我犯困,依旧严重影响我的工作。于是,医生减掉了我的安眠药,只给我开几粒,让我晚上睡不着的时候吃。到了今年五六月份的时候,也就是前几个月,我已经基本恢复了。同事们都说我不是刚进来时那个样子了。跟大家有说有笑的。工作起来也更轻松了。但是医生说药还得继续吃,起码要吃一年半以上才能停。事实证明,医生的话是没错的。上个月,我以为我已经痊愈了,想擅自停药,却发现,只要超过两天没吃药,我的病情就有复发的征兆。于是,只得听医生的话,继续吃药。(药不能停啊)
As clinicians, we routinely make critical decisions for our patients with depression. Because of the uncertainty of factors that affect diagnosis and treatment, clinicians may find an objective, quick measurement tool helpful. Measurementbased care (MBC) provides specific and objective information on which to base clinical decisions and should therefore enhance quality of care and treatment outcomes. (1-3) MBC rests on these assumptions. * Compared with general questions that are typically asked during a patient evaluation, specific measurements (administered by clinicians or self-reported by patients) provide more accurate information on which to establish a diagnosis, assess treatment outcomes, and modify treatments. * Patients who complete these measurement tests will better understand their disorder and treatment effects, which will enable them to better manage their depression. * Medical records that include the results of specific measurements will assist subsequent clinicians in understanding the results of prior treatments. * The routine use of the same measurements in practice and clinical research studies will help clinicians translate research findings into their own practices. * For most outpatients with depression, self-report methods are available that are free and that take little time and effort. Diagnostic measurements Researchers have used criterion-based diagnostic methods for years. After DSM-III was introduced in 1980, the Structured Clinical Interviews for DSM-III (SCID) (and later for DSMIV) were developed to obtain lifetime diagnoses. (4,5) Briefer structured interviews were then developed, including the Mini-International Neuropsychiatric Interview (MINI), which assesses only current diagnoses, and the MINI-Plus, which elicits information about current and past diagnoses. (6-8) The MINI takes 30 to 40 minutes to administer, while the MINI-Plus may take up to 60 minutes. Studies have shown that structured or semistructured interviews provide more accurate diagnoses than typical practice. For example, clinically rendered diagnoses were compared with those made based on SCID results. (9) Major diagnostic differences were found in 40% of outpatients with clinical diagnoses of schizophrenia or bipolar or major depressive disorders. In addition, when clinicians were provided with a diagnosis that was determined using SCID, they changed the chart diagnosis in a substantial proportion of cases and prescribed fewer medications. (10) Symptom measurements Once a diagnosis has been made and therapy has been initiated, the regimen must often be modified because of intolerance, adverse effects, or other less-than-desirable symptomatic outcomes. Medication and somatic therapies are typically aimed at treating symptoms, but psychotherapy and disease self-management may also address other aspects of treatment (eg, medication adherence, social/occupational function, self-esteem). The Texas Medication Algorithm Project (TMAP) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) studies showed that diligent assessment of symptoms and adverse effects enhances outcomes. (11-14) The goal of therapy for depression is symptom remission and, ultimately, sustained remission and functional recovery. (15) Most patients require more than 1 treatment revision (eg, altered dosage, treatment, or delivery). When implementing guideline-driven or evidencebased care, initial treatment is continued until remission or maximal symptom improvement is obtained or until the patient cannot tolerate the regimen. Thereafter, the dosage or type of treatment may...
本发明胶囊剂的制作过程为:取熟地1500g,合欢花1500g,柏子仁1500g,香附1500g,柴胡1500g,山药1500g,制首乌1500g,绞股蓝1500g ,栀子1500g,党参1500g,当归1500g,生牡蛎1500g,黄芪1500g,五味子UOOg,淫羊藿1500g,酸枣仁1500g,远志1500g,黄柏15()0g,金线莲l500g,钩藤1500g,力卩10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度约为1.08(2(TC);上述滤液经体积为IOL的大孔吸附树脂柱,先用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到组份药粉;装入胶嚢制为胶嚢剂,每粒胶嚢装0.3g。可以每12粒为一板。本发明颗粒剂的制作过程为:取熟地2000g,合欢花2000g,柏子仁2000g,香附2000g,柴胡2000g,山药2000g,制首乌2000g,绞股蓝2000g ,梔子2000g,党参2000g,当归2000g,生牡蛎2000g,黄芙2000g,五味子2000g,淫羊藿2000g,酸枣仁2000g,远志2000g g,黄柏20()()g,金线莲2000g,钩藤2000g,将所述组份按配比混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温下,与乙醇共同浸渍20天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液,加热浓缩至糊状,放入烘箱,控制在8(TC,烘干后冷却,粉碎后加入3000g淀粉混合,制粒、干燥、整粒、分装,包装得成品,每袋4〜6g包装。

抑郁症以往被划分为情感性精神病、其它类型的疾病均被划分为神经 症。抑郁症是一种持久的心境低落状态,常伴有焦虑、躯体不适感和睡眠障 碍,患者有治疗要求,而无明显的运动障碍、以及幻觉、幻想、思维和行为 紊乱等精神特征,生活能力无明显影响;神经症是一組表现心情抑郁、烦恼、 紧张、恐怖、疑病、强迫症状、分离和转换症状等,除意症表现为短的发作 性症状外, 一般病程迁延可达数年或数十年,可分为恐怖性神经症、焦虑性 神经症、强迫性神经症、抑郁性神经症、癔症、疑病性神经症、神经哀弱、 其它神经症(人格解体神经症、躯体化障碍、职业性如书写痉挛)等。依据中 医理论,抑郁症、焦虑症统称为精神和心理障碍性疾病,是由于植物神经功 能紊乱而导致心境低落、焦虑、失眠多梦,幻觉、妄想、思维和行为紊乱等 精神病特征。中医认为这些症状是因情志不遂,忧思悲怒,起居不慎,饮食 不节而造成。西医治疗多采取化学药物治疗,其疗效不稳定,副作用大;而中药以其毒性小,长期服用安全,越来越多的被人们认识用于治疗精神方面 的疾病。


Brintellix通用名Vortioxetine,是一种调节和促进血清素分泌类的药物,属于非典型性抗抑郁症药物,它的机制目前还不完全清楚,但是发现它同时起到血清素再摄取抑制剂、去甲肾上腺素再摄取抑制剂、5-HT 1A受体激动剂、5-HT 1B受体部分激动剂等功能。武田制药声称,这款药物是目前唯一通过这种综合性的功能来促进血清素水平的药物,虽然每一种功能对其发挥抗抑郁作用的贡献有多大,目前为止还不是很清楚,此药除了能够改善患者的情绪外,临床研究显示还能改善认知功能,对于目前市场上销售的抗抑郁症药物来说,这可以称得上是一种具有进步性的药物。此药由武田和丹麦的灵北制药公司共同销售,在这笔交易中武田支付灵北制药4000万美元的先期付款,另外总计高达3.45亿美元的里程碑付款。2013年先后在美国和欧盟上市,预测2017年销售额8.45亿美元, 2021年销售额为17.5亿美元。
×